time between RP and RT on the aforementioned adverse events, after adjusting for potential confounders.
INTRODUCTION AND OBJECTIVES: Multiparametric magnetic resonance imaging (mp-MRI) and Prostate Imaging Reporting and Data System (PI-RADS) score have been reported to be a likely radiographic biomarker for predicting treatment prognosis after radical prostatectomy. However, whether PI-RADS score can predict the outcome of radiotherapy for non-metastatic prostate cancer remains unclear. This study evaluated the usefulness of mp-MRI and PI-RADS score for predicting biochemical recurrence (BCR) in patients with prostate cancer treated with radiotherapy.
METHODS: Until April 2015, 517 patients underwent each intensity modulated radiotherapy (IMRT) or high-dose-rate (HDR) brachytherapy for non-metastatic prostate cancer. Of these patients, 234 who underwent mp-MRI before prostate biopsy were enrolled in this study. All the patients were classified as high-risk according to the D'Amico risk stratification. The total doses used for the IMRT was either 66 or 74Gy, HDR brachytherapy with external beam radiotherapy was 18 and 45 Gy, respectively. The patients also received neoadjuvant hormone therapy for 4 to 6 months and adjuvant hormone therapy for 6 months. The usefulness of mp-MRI was estimated by using PI-RADS version 2. We analyzed retrospectively the prognostic factor of BCR after radiotherapy.
RESULTS: The median age of the patients was 71 years, and the median prostate-specific antigen (PSA) level was 15.0ng/mL. The clinical T stage was T1c in 40 patients (17%), T2 in 82 (35%), and T3 in 112 (48%). Of the patients, 147 (63%) had a Gleason score of 8-10. Meanwhile, the PI-RADS score was 1-3 in 89 patients (38%), 4 in 69 (30%), and 5 in 76 (32%). The 147 patients underwent IMRT and 87 patients underwent HDR brachytherapy. BCR occurred in 12 patients after IMRT and 22 patients after HDR brachytherapy. In the multivariate Cox proportional hazards regression analysis, a PI-RADS score of 5 was the independent predictive factor of BCR after radiotherapy (p < 0.01).
CONCLUSIONS: Our study shows that a PI-RADS score of 5 is strongly associated with BCR after radiotherapy. Performing mp-MRI before prostate biopsy might be useful as a radiographic biomarker in patients with high-risk prostate cancer who undergo radiotherapy.
Source of Funding: none

MP72-05 COMPLICATIONS OF THE SPACEOAR HYDROGEL SYSTEM
Buddima Ranasinghe*, Brooklyn, NY; Beshoy Nazeer, West Indies, Grenada; David Silver, Ariel Schulman, Brooklyn, NY INTRODUCTION AND OBJECTIVES: The SpaceOAR System is a Food and Drug Administration-approved hydrogel injection used to create space between the prostate and rectum during prostate radiotherapy. The SpaceOAR has shown to significantly reduce the rectal radiation dose with lower rates of rectal toxicity. Despite a high safety performance in initial trials, the SpaceOAR remains in early clinical use. Thus, we examined emerging safety reports as the system becomes more widely utilized.
METHODS: We reviewed the SpaceOAR manufacturer website and manufacturer-sponsored physician symposia for the safety profile and complications associated with the SpaceOAR hydrogel. We then compared this with reports submitted to the Manufacturer and User Facility Device Experience (MAUDE) database.
RESULTS: The manufacturer website and physician symposia reported risks including pain, needle penetration and/or gel injection into a nearby organ or blood vessel, local inflammation, infection, urinary retention and local rectal injury or symptoms. There were 14
